MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.118
-0.308
-12.70%
Closed 16:00 11/15 EST
OPEN
2.380
PREV CLOSE
2.426
HIGH
2.440
LOW
2.020
VOLUME
73.71K
TURNOVER
--
52 WEEK HIGH
17.00
52 WEEK LOW
2.020
MARKET CAP
12.24M
P/E (TTM)
-0.9050
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PDSB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PDSB News

  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.2d ago
  • PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely
  • Simply Wall St..3d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About PDSB

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
More

Webull offers PDS Biotechnology Corp (PDSB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.